Jasper Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Jasper Therapeutics implemented a 1-for-30 reverse stock split, effective November 6, 2026 at 12:01 a.m. ET, reducing outstanding shares from approximately 33.3 million to 1.11 million. The split was approved by stockholders on September 30, 2026, with the board selecting a 1-for-30 ratio from an authorized 1-for-15 to 1-for-35 range on October 23, 2026. Fractional share holders receive cash payment based on the closing price on November 5, 2026; pro-rata ownership percentages remain unchanged except for fractional-share treatment effects.
Why this rating
Reverse split is routine capital structure action, common for Nasdaq compliance. No business operations, revenue, or asset changes; non-dilutive to ownership. Risk of future delisting and stock-price pressure post-split are real but this is a mechanical adjustment, not a material business event.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.